Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2007-05-08
2007-05-08
Andres, Janet L. (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Reexamination Certificate
active
11136429
ABSTRACT:
Intractable neuronal diseases are treated by inducing differentiation of neural stem cells into neurons without accompanying a risk such as cytotoxicity and infection. Intractable neuronal diseases, such as Parkinson's disease, cerebral infarction, Alzheimer's disease, spinal cord injury, brain contusion, amyotropic lateral sclerosis, Huntington's disease, malignant tumor, and the like, are treated by regeneration therapy by transferring VHL peptides which can induce differentiation of neural stem cell into neurons into neural stem cells to induce differentiation of neural stem cells into neurons or by administering VHL peptides directly into a human body to induce differentiation of endogeneous stem cells into neurons.
REFERENCES:
patent: 6084068 (2000-07-01), Conaway et al.
patent: 00/69908 (2000-11-01), None
patent: WO0191798 (2001-12-01), None
patent: WO03064609 (2003-08-01), None
Fuchs et al. Cell 2000. 100: 143-155.
H. Kanno et al., “Role of the von Hippel-Lindau Tumor Suppressor Protein during Neuronal Differentiation”,Cancer Research, vol. 60, pp. 2820-2824, 2000.
F. Latif et al., “Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene”,Science, vol. 260, pp. 1317-1320, 1993.
J. Gnarra et al., “Molecular Cloning of the von Hippel-Lindau Tumor Suppressor Gene and Its Role in Renal Carcinoma”,Biochemical et Biophysica Acta, vol. 1242, No. 3, pp. 201-210, 1996.
D. Watkins et al., “Genetics, Prognosis and Therapy of Central Nervous System Tumors”,Cancer Detection and Prevention, vol. 18, No. 2, pp. 139-144, 1994.
J. McDonald et al., “Transplanted Embryonic Stem Cells Survive, Differentiate and Promote Recovery in Injured Rat Spinal Cord”,Nature Medicine, vol. 5, No. 12, pp. 1410-1412, 1999.
Fisher, “Neural Precursor Cells: Applications for the Study and Repair of the Central Nervous Sysytem,”Neurobiology of Disease, vol. 4, pp. 1-22, 1997.
Murray et al., “Transgenic Animals in Agriculture”,CAB International: Oxon, pp. 59-60, 1999.
Isacson et al., “Benefits and risks of hosting animal cells in the human brain,”Nature Medicine, vol. 3, No. 9, pp. 964-969, 1997.
Kanno et al., “Regulation of Differentiation by VHL Gene in Neural Stem Cells and Cell Death”,Neuroimmunological Research, vol. 13, pp. 85-90, 2003 (including English Abstract).
Ohh et al., “Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein”,The Journal of Clinical Investigation, vol. 104, No. 11, pp. 1583-1591, 1999 (including English translation).
Asao, “Elongin BC complex that controls multiple intracellular functions”,Biochemistry, vol. 71, No. 4, pp. 279-282, 1999.
Tanaka, “The role of von Hippel-Lindau protein in the differentiation of neural progenitor cells under normoxic and anoxic conditions”,Neuroscience Letter, vol. 383, pp. 28-32, 2005.
Yamada et al., “Transfer of the von Hippel-Lindau Gene to Neuronal Progenitor Cells in Treatment for Parkinson's Disease”,Ann. Neurol., vol. 54, pp. 352-359, 2003.
Andres Janet L.
Hiroshi Kanno
Toagosei Co. Ltd.
Wang Chang-Yu
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
VHL peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with VHL peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VHL peptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3720793